文献速递肝病消化道肿瘤与早癌

单细胞RNA测序衍生特征定义晚期肝细胞癌对阿替利珠单抗联合贝伐珠单抗的应答模式

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2024-12-19

本研究利用单细胞RNA测序在晚期肝细胞癌中衍生出21种细胞表型的基因表达特征,并应用于422例接受阿替利珠单抗+贝伐珠单抗(n=317)对比阿替利珠单抗(n=47)或索拉非尼(n=58)治疗的RNA测序样本,揭示两种应答模式并定义「免疫 competent」和「血管生成驱动」分子亚组及原发耐药特征。

要点

  • 阿替利珠单抗+贝伐珠单抗为晚期肝细胞癌当前标准治疗,中位总生存期19.2个月。
  • 免疫介导应答特征为CD8+ T效应细胞与促炎CXCL10+巨噬细胞共存,代表免疫丰富微环境。
  • 非免疫血管生成相关应答以VEGF共受体神经纤毛蛋白-1(NRP1)表达降低为特征,可预测阿替利珠单抗+贝伐珠单抗对比索拉非尼的总生存期改善(p=0.039)。

核心结论

  • 研究揭示晚期肝细胞癌对阿替利珠单抗+贝伐珠单抗临床获益的两个不同分子亚组(「免疫 competent」和「血管生成驱动」)以及原发耐药的主要特征,提供基于临床结局分层患者的分子框架并指导克服耐药的潜在策略。

研究设计与样本

  • 利用单细胞RNA测序在晚期肝细胞癌中衍生出重现21种细胞表型的基因表达特征。
  • 这些特征应用于422例晚期肝细胞癌患者的RNA测序样本,其中接受阿替利珠单抗+贝伐珠单抗治疗n=317,对照为阿替利珠单抗n=47或索拉非尼n=58。

主要发现

  • 发现两种不同的阿替利珠单抗+贝伐珠单抗应答模式:免疫介导应答(CD8+ T效应细胞与促炎CXCL10+巨噬细胞共存)和非免疫血管生成相关应答(NRP1表达降低)。
  • NRP1表达降低可特异性预测阿替利珠单抗+贝伐珠单抗对比索拉非尼的总生存期改善(p=0.039)。
  • 原发耐药与免疫抑制性髓系群体(CD14+单核细胞和TREM2+巨噬细胞)富集及Notch通路激活相关。
  • 基于机制定义「免疫 competent」和「血管生成驱动」分子亚组,每个亚组接受阿替利珠单抗+贝伐珠单抗对比索拉非尼均与显著更长的总生存期相关(交互作用p=0.027),并定义「耐药」亚组。

关键数值与推荐

  • 阿替利珠单抗+贝伐珠单抗提供中位总生存期19.2个月。
  • NRP1表达降低预测阿替利珠单抗+贝伐珠单抗对比索拉非尼的总生存期改善(p=0.039)。
  • 「免疫 competent」和「血管生成驱动」亚组接受阿替利珠单抗+贝伐珠单抗对比索拉非尼的总生存期交互作用p=0.027。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit vs. resistance to atezo+bev. METHODS: We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of patients with advanced HCC treated with atezo+bev (n = 317) vs. atezolizumab (n = 47) or sorafenib (n = 58) as comparators. RESULTS: We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterised by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune-rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs. sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define "Immune-competent" and "Angiogenesis-driven" molecular subgroups, each associated with a significantly longer OS with atezo+bev vs. sorafenib (p of interaction = 0.027), and a "Resistant" subset. CONCLUSION: Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC ("Immune-competent" and "Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance. IMPACT AND IMPLICATIONS: Atezolizumab + bevacizumab (atezo+bev) is standard of care in advanced hepatocellular carcinoma (HCC), yet molecular determinants of clinical benefit to the combination remain unclear. This study harnesses the power of single-cell RNA sequencing, deriving gene expression signatures representing 21 cell subtypes in the advanced HCC microenvironment. By applying these signatures to RNA-sequencing samples, we reveal two distinct response patterns to atezo+bev and define molecular subgroups of patients ("Immune-competent" and "Angiogenesis-driven" vs. "Resistant") with differential clinical outcomes upon treatment with atezo+bev, pointing towards the role of immunosuppressive myeloid cell types and Notch pathway activation in primary resistance to atezo+bev. These results may help refine treatment strategies and improve outcomes for patients with advanced HCC, while also guiding future research aimed at overcoming resistance mechanisms.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cappuyns S, Piqué-Gili M, Esteban-Fabró R, et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J Hepatol. 2024. PMID: 39709141. doi:10.1016/j.jhep.2024.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。